Betta Pharmaceuticals Co Ltd Working Capital to Net Assets Ratio

Latest as of March 2026: -0.2%

Betta Pharmaceuticals Co Ltd working capital to net assets ratio. Betta Pharmaceuticals Co Ltd (300558) has a Working Capital to Net Assets ratio of -0.2% as of March 2026. Working capital of CN¥-15.94 Million (current assets of CN¥1.67 Billion minus current liabilities of CN¥1.69 Billion) is measured against net assets of CN¥6.86 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.

WC/NA Ratio

-0.2%
Working Capital / Net Assets

Working Capital

CN¥-15.94 Million
CNY

Current Assets

CN¥1.67 Billion
CNY

Current Liabilities

CN¥1.69 Billion
CNY

Working Capital to Net Assets Ratio of Betta Pharmaceuticals Co Ltd (2011–2025)

Working capital to net assets ratio of Betta Pharmaceuticals Co Ltd from 2011 to 2025. This chart shows how Betta Pharmaceuticals Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at -0.2%, reflecting working capital of CN¥-15.94 Million against net assets of CN¥6.86 Billion CNY. Explore Betta Pharmaceuticals Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.

Betta Pharmaceuticals Co Ltd Working Capital to Net Assets Ratio by Year (2011–2025)

Betta Pharmaceuticals Co Ltd working capital to net assets ratio by year from 2011 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Betta Pharmaceuticals Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see balance sheet size of Betta Pharmaceuticals Co Ltd.

Year WC/NA Ratio Working Capital (CNY) Net Assets Current Assets Current Liabilities Change (pp)
2025 -5.1% CN¥-339.45 Million CN¥6.67 Billion CN¥1.58 Billion CN¥1.92 Billion ▲ +5.9 pp
2024 -11.0% CN¥-623.63 Million CN¥5.67 Billion CN¥1.22 Billion CN¥1.85 Billion ▼ -5.8 pp
2023 -5.2% CN¥-277.28 Million CN¥5.35 Billion CN¥1.53 Billion CN¥1.80 Billion ▲ +2.3 pp
2022 -7.5% CN¥-371.95 Million CN¥4.96 Billion CN¥1.73 Billion CN¥2.10 Billion ▼ -23.8 pp
2021 16.3% CN¥765.08 Million CN¥4.69 Billion CN¥1.65 Billion CN¥888.86 Million ▼ -17.6 pp
2020 33.9% CN¥1.40 Billion CN¥4.14 Billion CN¥1.85 Billion CN¥443.05 Million ▲ +30.4 pp
2019 3.5% CN¥87.04 Million CN¥2.47 Billion CN¥792.24 Million CN¥705.20 Million ▲ +11.4 pp
2018 -7.9% CN¥-176.35 Million CN¥2.24 Billion CN¥574.76 Million CN¥751.11 Million ▼ -7.3 pp
2017 -0.5% CN¥-10.66 Million CN¥2.07 Billion CN¥506.53 Million CN¥517.19 Million ▼ -57.4 pp
2016 56.9% CN¥1.10 Billion CN¥1.93 Billion CN¥1.30 Billion CN¥205.42 Million ▲ +9.7 pp
2015 47.2% CN¥421.84 Million CN¥893.95 Million CN¥560.21 Million CN¥138.37 Million ▲ +15.0 pp
2014 32.1% CN¥174.57 Million CN¥543.03 Million CN¥261.51 Million CN¥86.94 Million ▼ -20.0 pp
2013 52.1% CN¥166.30 Million CN¥319.10 Million CN¥222.98 Million CN¥56.68 Million ▲ +56.3 pp
2012 -4.2% CN¥-7.23 Million CN¥172.56 Million CN¥63.78 Million CN¥71.02 Million ▲ +147.1 pp
2011 -151.3% CN¥-79.08 Million CN¥52.28 Million CN¥40.22 Million CN¥119.30 Million —
pp = percentage points